Guggenheim initiated coverage of Pyxis Oncology (PYXS) with a Buy rating and $5 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYXS:
- Optimistic Buy Rating for Pyxis Oncology Driven by Promising MICVO Developments and Strategic Merck Collaboration
- Buy Rating for Pyxis Oncology: Promising Prospects for Micvo and Strong Financial Position
- Pyxis Oncology Reports Q2 2025 Financial Results
- Pyxis Oncology reports Q2 EPS (30c), consensus (35c)
- Pyxis Oncology Updates Phase 1 Trial Enrollment